Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDPHL01 in male androgenetic alopecia
NCT06724614Phase 3Active, not recruiting
- Sponsor
- Veradermics
- Start
- Nov 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of VDPHL01 in androgenetic alopecia (AGA) (4 arms), sponsored by Veradermics. Primary endpoints: Target Area Hair Counts (non-vellus) at 6 months and Subject Evaluation of Treatment Benefit at 6 months. Started Nov 2024; status: active, not recruiting.
02
Drugs
VDPHL01
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT06724614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724614.